ES2075893T3 - Activacion in vivo especifica de sede de farmacos terapeuticos. - Google Patents

Activacion in vivo especifica de sede de farmacos terapeuticos.

Info

Publication number
ES2075893T3
ES2075893T3 ES90902934T ES90902934T ES2075893T3 ES 2075893 T3 ES2075893 T3 ES 2075893T3 ES 90902934 T ES90902934 T ES 90902934T ES 90902934 T ES90902934 T ES 90902934T ES 2075893 T3 ES2075893 T3 ES 2075893T3
Authority
ES
Spain
Prior art keywords
activator
prodrug
target tissue
targeting moiety
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90902934T
Other languages
English (en)
Inventor
Reinhard Bredehorst
Chong-Ho Kim
Richard Mccabe
Nicholas Pomato
Carl-Wilhelm Vogel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23161497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2075893(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of ES2075893T3 publication Critical patent/ES2075893T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UN METODO DE ACTIVACION EN-VIVO ESPECIFICA DEL EMPLAZAMIENTO DE UNA PRODROGA EN UN ANIMAL UTILIZANDO UN CONJUGADO DE MITAD DE BLANCO ACTIVADOR PARA LOCALIZAR UN ACTIVADOR EN UN EMPLAZAMIENTO PREDETERMINADO DE USO Y UN COMPUESTO PRODROGA QUE ES TRANSFORMADO EN UNA DROGA ACTIVA ANTE LA PRESENCIA DEL ACTIVADOR. EN UNA PUESTA EN PRACTICA PREFERIDA DE LA INVENCION, LA MITAD DE BLANCO, EL ACTIVADOR Y LA PRODROGA MUESTRAN POCA O NINGUNA INMUNOGENIACIDAD EN EL ANIMAL QUE ESTA SIENDO TRATADO. LA MITAD DE BLANCO ES RELATIVAMENTE MAS ESPECIFICA PARA ENLAZARSE AL TEJIDO DE BLANCO QUE A UN TEJIDO SIN BLANCO. EL ACTIVADOR NO SE ENCUENTRA O NO ESTA PRESENTE EN SOLO PEQUEÑAS CANTIDADES EN CIRCULACION O EN TEJIDOS SIN BLANCO, NO TIENE UN SUSTRATO PARA SU ACTIVIDAD EN CIRCULACION O EN TEJIDO SIN BLANCO, PUEDE SER ENLAZADO A LA MITAD DE BLANCO Y ES CAPAZ DE TRANSFORMAR LA PRODROGA EN UNA DROGA ACTIVA. LA PRODROGA ES SELECCIONADA POR SU CAPACIDAD DE EJERCER UNA ACTIVIDAD CITOXICA EN EL TEJIDO DE BLANCO DESPUESDE HABER SIDO TRANSFORMADA POR EL ACTIVADOR.
ES90902934T 1989-01-23 1990-01-23 Activacion in vivo especifica de sede de farmacos terapeuticos. Expired - Lifetime ES2075893T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30099989A 1989-01-23 1989-01-23

Publications (1)

Publication Number Publication Date
ES2075893T3 true ES2075893T3 (es) 1995-10-16

Family

ID=23161497

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90902934T Expired - Lifetime ES2075893T3 (es) 1989-01-23 1990-01-23 Activacion in vivo especifica de sede de farmacos terapeuticos.

Country Status (12)

Country Link
EP (1) EP0454783B1 (es)
JP (1) JP3273608B2 (es)
KR (1) KR0185967B1 (es)
AT (1) ATE123414T1 (es)
AU (1) AU648015B2 (es)
CA (1) CA2025899A1 (es)
DE (1) DE69019959T2 (es)
DK (1) DK0454783T3 (es)
ES (1) ES2075893T3 (es)
FI (1) FI97692C (es)
NO (1) NO912864L (es)
WO (1) WO1990007929A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
DK0436717T3 (da) * 1989-08-02 2003-05-05 Mitra Medical Technology Ab System til anvendelse ved en fremgangsmåde til terapeutisk eller diagnostisk behandling
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US6610299B1 (en) 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
EP0505357B1 (en) * 1989-12-11 1999-03-10 Immunomedics, Inc. Method for antibody targeting of diagnostic or therapeutic agents
SE9100142L (sv) 1991-01-17 1992-07-18 Bengt Sandberg En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
AU4663493A (en) * 1992-07-06 1994-01-31 Hybritech Incorporated Method for delivery of cytotoxic agents and components thereof
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
CN1095677C (zh) * 1994-12-23 2002-12-11 曾尼卡有限公司 化合物
CN1193278A (zh) 1995-08-16 1998-09-16 曾尼卡有限公司 化合物
EP0795334B1 (de) * 1996-03-12 2006-02-01 Sanofi-Aventis Deutschland GmbH Neuartige Prodrugs für die Therapie von Tumoren und entzündlichen Erkrankungen
PL229108B1 (pl) * 2014-08-22 2018-06-29 Celther Polska Spolka Z Ograniczona Odpowiedzialnoscia Sposób wydzielania i oczyszczania estrów chityny (mono-, di‑podstawionych) oraz kopoliestrów chityny z mieszanin poreakcyjnych

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067774A (en) * 1971-05-14 1978-01-10 Syva Company Compounds for enzyme amplification assay
LU85581A1 (fr) * 1984-10-10 1986-06-11 Smb Lab Ensembles d'anticorps monoclonaux diriges contre la lactoferrine humaine et le lysozyme humain
JPS62138496A (ja) * 1985-12-11 1987-06-22 Ihara Chem Ind Co Ltd キチンオリゴマ−の製造方法
HU213222B (en) * 1987-07-02 1997-03-28 Akzo Nv Method for producing of tumor antigen recognized by monoclonal antibody, antibody directed against antigen anp antibody specific to antiidiotypic antigen
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
ZA893284B (en) * 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies

Also Published As

Publication number Publication date
JP3273608B2 (ja) 2002-04-08
EP0454783B1 (en) 1995-06-07
NO912864D0 (no) 1991-07-22
CA2025899A1 (en) 1990-07-24
JPH04503068A (ja) 1992-06-04
AU5039790A (en) 1990-08-13
FI97692C (fi) 1997-02-10
EP0454783A1 (en) 1991-11-06
EP0454783A4 (en) 1992-01-15
FI913511A0 (fi) 1991-07-22
KR910700072A (ko) 1991-03-13
FI97692B (fi) 1996-10-31
NO912864L (no) 1991-09-19
WO1990007929A1 (en) 1990-07-26
AU648015B2 (en) 1994-04-14
KR0185967B1 (ko) 1999-05-01
ATE123414T1 (de) 1995-06-15
DE69019959T2 (de) 1995-10-05
DK0454783T3 (da) 1995-10-16
DE69019959D1 (de) 1995-07-13

Similar Documents

Publication Publication Date Title
ES2075893T3 (es) Activacion in vivo especifica de sede de farmacos terapeuticos.
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
NO20034684D0 (no) Innretning for administrering av midler gjennom stratum corcum
DE3277453D1 (en) Use of eucalyptol for enhancing skin permeation of bioaffecting agents
DE69232263D1 (de) Radikalfänger ("spin traps") zur behandlung von mit oxidation von lipiden und proteinen verbundenen erkrankungen
RU95109905A (ru) Композиции в жидком, полутвердом, твердом, гелеобразном или пастообразном виде и способ лечения заболеваний полости рта
GB9710049D0 (en) Method
BR0109446A (pt) Medicamento para a aplicação intracorpórea, uso de um xanteno halogenado, composição farmacêutica, e, método de tratamento
HU9602356D0 (en) Drug targeting system, method for preparing same and its use
UA19808A (uk) Спосіб одержаhhя феhілалкіламіhів або солей цих сполук
DK164441C (da) Anvendelse af et piperidinderivat til fremstilling af et farmaceutisk praeparat til behandling af smertetilstande
DE59902270D1 (de) Feuchtigkeitsaktivierbares therapeutisches system
DE69322251T2 (de) Medizinische zusammensetzung
HU229598B1 (en) Preparations for the application of anti-inflammatory agents
Newell Pharmacokinetically guided dose escalation in phase I clinical trials: Commentary and proposed guidelines.
DK0559145T3 (da) Lægemiddel til truende abort
AU5643299A (en) Humic acid and its use in the treatment of various conditions
Bredehorst et al. Site specific in vivo activation of therapeutic drugs
IT1158029B (it) Preparato per ridurre traumi dei tessuti in esseri umani o animali e procedeminto per la sua produzione
FR2700543B1 (fr) Sels de dérivés de 4-pyrimidinone, leur préparation et leur application en thérapeutique.
DK452788D0 (da) Smertestillende praeparat
GB2019720A (en) S-adenosyl-L-homocysteine and salts thereof for use in therapy
KR890007737A (ko) 진토작용을 하는 약제
DE69724228D1 (de) Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten
MX9707478A (es) Composicion y proceso para la prevencion y el tratamiento de reacciones cutaneas de hipersensibilidad inmediata.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 454783

Country of ref document: ES